Last reviewed · How we verify

Elexacaftor-tezacaftor-ivacaftor exposure

Jennifer Taylor-Cousar · Phase 2 active Small molecule

Elexacaftor-tezacaftor-ivacaftor exposure is a CFTR potentiator Small molecule drug developed by Jennifer Taylor-Cousar. It is currently in Phase 2 development for Cystic fibrosis.

CFTR potentiator

CFTR potentiator Used for Cystic fibrosis.

At a glance

Generic nameElexacaftor-tezacaftor-ivacaftor exposure
SponsorJennifer Taylor-Cousar
Drug classCFTR potentiator
TargetCFTR
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 2

Mechanism of action

Elexacaftor, tezacaftor, and ivacaftor work together to increase the amount of functional CFTR protein at the cell surface, leading to improved chloride transport and mucociliary clearance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Elexacaftor-tezacaftor-ivacaftor exposure

What is Elexacaftor-tezacaftor-ivacaftor exposure?

Elexacaftor-tezacaftor-ivacaftor exposure is a CFTR potentiator drug developed by Jennifer Taylor-Cousar, indicated for Cystic fibrosis.

How does Elexacaftor-tezacaftor-ivacaftor exposure work?

CFTR potentiator

What is Elexacaftor-tezacaftor-ivacaftor exposure used for?

Elexacaftor-tezacaftor-ivacaftor exposure is indicated for Cystic fibrosis.

Who makes Elexacaftor-tezacaftor-ivacaftor exposure?

Elexacaftor-tezacaftor-ivacaftor exposure is developed by Jennifer Taylor-Cousar (see full Jennifer Taylor-Cousar pipeline at /company/jennifer-taylor-cousar).

What drug class is Elexacaftor-tezacaftor-ivacaftor exposure in?

Elexacaftor-tezacaftor-ivacaftor exposure belongs to the CFTR potentiator class. See all CFTR potentiator drugs at /class/cftr-potentiator.

What development phase is Elexacaftor-tezacaftor-ivacaftor exposure in?

Elexacaftor-tezacaftor-ivacaftor exposure is in Phase 2.

What are the side effects of Elexacaftor-tezacaftor-ivacaftor exposure?

Common side effects of Elexacaftor-tezacaftor-ivacaftor exposure include Nausea, Vomiting, Diarrhea, Headache, Fatigue.

What does Elexacaftor-tezacaftor-ivacaftor exposure target?

Elexacaftor-tezacaftor-ivacaftor exposure targets CFTR and is a CFTR potentiator.

Related